drugset / Trial / NCT00800787
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
NaSingle-groupOpen-labelTreatment
Summary
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
Timeline
- Start
- 2010-04
- Primary completion
- 2010-08
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hepatitis B immune globulin | Protein / enzyme biologic | 500 iu | Subcutaneous |
| Subject | hepatitis B immune globulin | Protein / enzyme biologic | 1000 iu | Subcutaneous |